EVALUATING THE CLINICAL AND HEMODYNAMICAL ACTION OF NEBIVOLOL IN CHRONIC HEART FAILURE
A task of this research was to study the influence of nebivolol on hemodynamic parameters, clinical sympthoms and life quality in patients II-IV FK HD by NYHA. 24 patients of main group have taken nebivolol in daily dose of 2,5-5 mg per os. Patients were treated with the drug in a course of 3 months...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2001-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A task of this research was to study the influence of nebivolol on hemodynamic parameters, clinical sympthoms and life quality in patients II-IV FK HD by NYHA. 24 patients of main group have taken nebivolol in daily dose of 2,5-5 mg per os. Patients were treated with the drug in a course of 3 months.A control group(15 people) was treated traditional therapy (by heart glicozides, metabolic preparations, diurethics, if necessary). We have found that new β-adrenoblocker with additional vasodilatatorial qualities- nebivolol (NEBILET) kindly influences main hemodinamic parameters in chronic coronary patients. During 3 months’ observation examined patients had KDR and KSR distinctly lowered, speed of shortening of miocardium fibrem and the function of throw and MV grew, tension in a pulmonary artery decreased. NEBILET’S prescription in dosage of 2,5-5 mg/ daily kindly influences the reduction of heart rythm’s disturbances, a distinct tendency to lowering of MMLV noted. NEBILET can be successfully used in a combinated therapy of CCD II-IV FK, its usage in cases of coronary deficiency and AG is mostly advisable. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |